Recently, Contrafect, an antibiotic biotech company developing a novel product for the treatment of severe staphylococcal infections, suffered a failure in its phase 3 trial. The trail was designed to show the superiority of its new drug over standard treatments. Why is it so hard to show that one antibiotic works better than another in a clinical trial?
